Advertisement
U.S. Markets closed
S&P Futures
6,002.75 -1.00 (-0.02%) Dow Futures
43,904.00 -6.00 (-0.01%) Nasdaq Futures
21,225.75 +1.00 (+0.00%) Russell 2000 Futures
2,397.40 +1.70 (+0.07%) Crude Oil
71.89 -0.47 (-0.65%) Gold
2,706.20 +0.40 (+0.01%)
Aprea Therapeutics, Inc. (APRE)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 3.9900 |
| Open | 3.9100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.9100 - 4.1500 |
| 52 Week Range | 2.1500 - 8.8470 |
| Volume | |
| Avg. Volume | 21,571 |
| Market Cap | 21.619M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9300 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.67 |
ZacksAprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 14.67% and 21.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash equivalents as of September 30, 2024 with cash runway for at least twelve months DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a cl
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.